You Kyung Eun, Koo Min-Ah, Lee Dae-Hyung, Kwon Byeong-Ju, Lee Mi Hee, Hyon Suong-Hyu, Seomun Young, Kim Jong-Tak, Park Jong-Chul
Cellbiocontrol Laboratory, Department of Medical Engineering, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.
Biomed Mater. 2014 Apr;9(2):025002. doi: 10.1088/1748-6041/9/2/025002. Epub 2014 Jan 31.
Many types of hemostatic agents have been studied for the effective control of bleeding. In this study, a powdery medical adhesive composed of aldehyded dextran and ε-poly (L-lysine) was used with the recombinant batroxobin. Batroxobin is a venomous component from the snake Bothrops atrox moojeni and catalyzes fibrinogen conversion to form soluble fibrin clots. This research aims to examine the performance of the batroxobin-containing adhesive for hemostasis, and evaluate its potential as a novel hemostatic adhesive. The fibrinogen conversion ability of batroxobin was evaluated by a fibrinogen clotting assay and a whole blood clotting assay. Both experiments demonstrated the effectiveness of the batroxobin-containing adhesive for blood clot formation. Animal experiments were also conducted. After a pricking wound was made in an ICR (imprinting control region) mouse liver, the adhesive and various concentrations of batroxobin were applied. The total amount of blood loss was reduced with increasing concentrations of batroxobin. For excessive bleeding conditions, the femoral artery wound model of SD (Sprague-Dawley) rats was adopted. With higher concentrations of batroxobin, hemostasis was more rapidly achieved. Histological analysis of the liver model also supports the hemostatic effects through fibrin clot formation. In conclusion, batroxobin and medical adhesive effectively facilitate blood coagulation, and could be developed for clinical use.
为有效控制出血，人们对多种止血剂进行了研究。在本研究中，一种由醛化葡聚糖和ε-聚（L-赖氨酸）组成的粉末状医用粘合剂与重组巴曲酶一起使用。巴曲酶是一种来自矛头蝮蛇（Bothrops atrox moojeni）的有毒成分，可催化纤维蛋白原转化形成可溶性纤维蛋白凝块。本研究旨在考察含巴曲酶粘合剂的止血性能，并评估其作为新型止血粘合剂的潜力。通过纤维蛋白原凝血试验和全血凝血试验评估巴曲酶的纤维蛋白原转化能力。两个实验均证明了含巴曲酶粘合剂在形成血凝块方面的有效性。还进行了动物实验。在ICR（印记对照区）小鼠肝脏上制造刺伤伤口后，应用粘合剂和不同浓度的巴曲酶。随着巴曲酶浓度的增加，失血量总量减少。对于出血过多的情况，采用SD（斯普拉格-道利）大鼠股动脉伤口模型。巴曲酶浓度越高，止血越快。肝脏模型的组织学分析也支持通过纤维蛋白凝块形成实现止血效果。总之，巴曲酶和医用粘合剂可有效促进血液凝固，有望开发用于临床。
